RU2016134404A3 - - Google Patents

Download PDF

Info

Publication number
RU2016134404A3
RU2016134404A3 RU2016134404A RU2016134404A RU2016134404A3 RU 2016134404 A3 RU2016134404 A3 RU 2016134404A3 RU 2016134404 A RU2016134404 A RU 2016134404A RU 2016134404 A RU2016134404 A RU 2016134404A RU 2016134404 A3 RU2016134404 A3 RU 2016134404A3
Authority
RU
Russia
Application number
RU2016134404A
Other versions
RU2677660C2 (ru
RU2016134404A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016134404A publication Critical patent/RU2016134404A/ru
Publication of RU2016134404A3 publication Critical patent/RU2016134404A3/ru
Application granted granted Critical
Publication of RU2677660C2 publication Critical patent/RU2677660C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41Preparation of salts of carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04Monocyclic monocarboxylic acids
    • C07C63/06Benzoic acid
    • C07C63/08Salts thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2016134404A 2014-01-24 2015-01-26 КРИСТАЛЛИЧЕСКАЯ ФОРМА α МОНОБЕНЗОАТА СОЕДИНЕНИЯ А, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩАЯ ЕЕ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ RU2677660C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410037009 2014-01-24
CN201410037009.X 2014-01-24
PCT/CN2015/071525 WO2015110077A1 (zh) 2014-01-24 2015-01-26 化合物A单苯甲酸盐的晶型α及其制备方法和含有该晶型的药物组合物

Publications (3)

Publication Number Publication Date
RU2016134404A RU2016134404A (ru) 2018-03-01
RU2016134404A3 true RU2016134404A3 (ru) 2018-08-15
RU2677660C2 RU2677660C2 (ru) 2019-01-18

Family

ID=53680849

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016134404A RU2677660C2 (ru) 2014-01-24 2015-01-26 КРИСТАЛЛИЧЕСКАЯ ФОРМА α МОНОБЕНЗОАТА СОЕДИНЕНИЯ А, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩАЯ ЕЕ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ

Country Status (5)

Country Link
CN (1) CN104803971B (ru)
BR (1) BR112016017087B1 (ru)
MX (1) MX366651B (ru)
RU (1) RU2677660C2 (ru)
WO (1) WO2015110077A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106349215B (zh) * 2015-07-15 2022-02-08 深圳信立泰药业股份有限公司 一种化合物a苯甲酸盐的无定形及其制备方法和含有该无定形的药物组合物
CN106349216B (zh) * 2015-07-15 2020-09-11 深圳信立泰药业股份有限公司 化合物A的晶型α及其制备方法和含有该晶型的药物组合物
WO2018219295A1 (zh) * 2017-05-31 2018-12-06 深圳信立泰药业股份有限公司 二肽基肽酶iv抑制剂的氘代1,2,4-三嗪衍生物
CN109692164A (zh) * 2017-10-20 2019-04-30 深圳信立泰药业股份有限公司 化合物a或其盐的药物组合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2805953B1 (en) * 2004-12-21 2016-03-09 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
CA2622642C (en) * 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
FR2933979B1 (fr) * 2008-07-15 2012-08-24 Pf Medicament Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine
CN102791701B (zh) * 2009-12-30 2014-02-12 深圳信立泰药业股份有限公司 作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物
BR112012028906A2 (pt) * 2010-05-12 2016-07-26 Mapi Pharma Ltd polimorfos de benzoato de alogliptina
CN103172615A (zh) * 2013-03-29 2013-06-26 山东罗欣药业股份有限公司 苯甲酸阿格列汀晶型化合物

Also Published As

Publication number Publication date
BR112016017087B1 (pt) 2022-12-27
BR112016017087A2 (pt) 2017-08-08
CN104803971A (zh) 2015-07-29
BR112016017087A8 (pt) 2018-04-17
WO2015110077A1 (zh) 2015-07-30
MX366651B (es) 2019-07-17
RU2677660C2 (ru) 2019-01-18
RU2016134404A (ru) 2018-03-01
MX2016009667A (es) 2017-02-28
CN104803971B (zh) 2021-11-30

Similar Documents

Publication Publication Date Title
BR112016021800A2 (ru)
BR112016018389A2 (ru)
BR112016027902A2 (ru)
BR112016016094A2 (ru)
BR112016023263A2 (ru)
BR112016028002A2 (ru)
BR112016019589A2 (ru)
BR112016027622A2 (ru)
BR112016017679A2 (ru)
BR112016022609A2 (ru)
BR112016019666A2 (ru)
BR112016027032A2 (ru)
BR112016020810A2 (ru)
BR112016015668A2 (ru)
BR112016017512A2 (ru)
BR112016026668A2 (ru)
CN302703483S (ru)
CN302713575S (ru)
CN302700769S (ru)
CN302702116S (ru)
CN302702139S (ru)
CN302703136S (ru)
CN302703161S (ru)
CN302703438S (ru)
CN302698781S (ru)

Legal Events

Date Code Title Description
HE4A Change of address of a patent owner

Effective date: 20220114